寻找英国供应商

Fitabeo Therapeutics是一家临床阶段制药公司，专注于开发和商业化创新药物，为现有治疗方案不能满足其适应症的人群，提供更好的健康结果。Fitabeo利用创新科技开发药物，以期实现分散式患者护理并减少医疗服务开销。 Fitabeo Therapeutics is a clinical-stage pharmaceutical company that develops and commercialises innovative medicines focusing on indications where existing treatments are inadequate for the target population to provide better health outcomes. It deploys innovative technologies to develop medicines that are expected to enable decentralised patient care and provide significant healthcare savings.

Cizzle正在开发一种肺癌早筛的血液检测方法。该公司是约克大学的衍生公司，成立于2006年，基于Coverley教授及其同事的工作发现。它的概念验证原型测试是基于检测一种稳定的血浆生物标志物的能力，一种被称为CIZ1B的CIZ1变体。CIZ1是一种天然存在的参与DNA复制的细胞核蛋白，而靶向的CIZ1B变异与早期肺癌高度相关。 Cizzle Biotechnology is developing a blood test for the early detection of lung cancer. The Company is a spin- out from the University of York, founded in 2006, around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer. 

Charles River旗下的Retrogenix细胞微阵列能够发现原代细胞表面受体以及潜在的脱靶细胞。经过10多年的扩展和完善，我们的细胞微阵列库现在有超过6500种蛋白质用于筛选，包括高于98%的怀孕8-10周的产前蛋白质。利用最大的市售质膜和人类细胞中表达的分泌蛋白，发现高质量、可开发的药物靶点和作用机制。该技术可用于多种生物制剂，包括抗体、蛋白质、小分子、病毒、CAR疗法和其他配体。结合抗体和细胞治疗开发平台的全面组合，Charles River可以加速您的药物开发管道，从候选药物选择到安全性评估等。 The Retrogenix Cell Microarray enables the discovery of primary cell surface receptors as well as potential off-targets. With over 10 years of expansion and refinement, our cell microarray libraries now have over 6,500 proteins for screening, including >98% of prenatal proteins present at 8-10 weeks of pregnancy. Discover high quality, exploitable drug targets and mechanisms of action using the largest commercially available set of plasma membrane and secreted proteins expressed in human cells. The technology can be used with a wide variety of biologics including antibodies, proteins, small molecules, viruses, CAR therapeutics, and other ligands. Together with an exhaustive portfolio for antibody and cellular therapeutic development platforms, Charles River can accelerate your drug development pipelines from candidate selection to safety assessment and beyond.

Woodley BioReg成立于2000年，致力于帮助制药、生物制药/生物仿制药、医疗保健和医疗器械公司开发和生产高质量的产品，为全球患者提供有效和安全的产品。Woodley BioReg与世界各地的客户合作，从世界上最大的制药公司到新兴的生物技术公司。我们利用在CMC、法规事务、GMP/QA和临床等各个方面的实践经验来加速药品的开发和批准。 Woodley BioReg利用其完善的cGMP认证流程和具有商业竞争力的监管批准策略，帮助其客户在全球范围内成功注册药物，包括在英国和欧盟。在自己的MHRA GMP许可下，Woodley BioReg使其国际客户能够将其产品出口到英国和欧盟进行分销。 Founded in 2000, Woodley BioReg is dedicated to helping pharmaceutical, biopharmaceutical /biosimilar, healthcare and medical device companies develop and manufacture high quality products that are effective and safe for patients worldwide. Woodley BioReg works with a wide range of clients around the world, from the world's largest pharmaceutical companies to start-up biotechnology organisations.  We use our hands-on experience in all aspects of CMC, Regulatory Affairs, GMP/QA and Clinical to accelerate the development and approval of medicinal products. Woodley BioReg helps its clients to successfully register drugs worldwide including in the UK and EU using its well-established process for cGMP certification and commercially competitive regulatory approval strategies.  Under its own MHRA GMP licence, Woodley BioReg enables its international clients to export their products to the UK and EU for distribution.   

Fulkrum技术资源公司（FTR)致力于与客户展开深度合作，为其提供竞争优势，使其交付更多成功的项目。从最初的可行性研究与设计（FEED）到最终的执行和运营，公司客户可以获得各种各样的全球资源，最大限度地提高自身能力，确保项目安全、及时交付并具有成本效益。

在如今快速发展的能源行业，需要严格管理整个供应链以确保项目无缝交付。在不断的尝试和验证后，FTR拥有了遍布全球的资源，使客户对各个供应商、测试机构及项目的后勤阶段有全面的了解和监控，可以保证在紧凑的时间里高质量完成项目交付。

FTR在全球市场提供可靠、有效的监测服务，拥有大型项目管理的丰富经验，可以在短时间内提供预经筛选和获准的资源，使客户可以获得全球供应商普遍应用的知识和经验。